Overview

Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)

Status:
Withdrawn
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of sobetirome, a selective thyroid hormone analog, in adult male X-ALD patients.
Phase:
Phase 1
Details
Lead Sponsor:
Thomas S. Scanlan